NCT01114607 - A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 5, 2010

Primary Completion Date

June 29, 2010

Study Completion Date

June 29, 2010

Conditions

Crohn's Disease

Interventions

DRUG

GSK1605786 ChemoCentryx: formulation A

ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.

DRUG

GSK1605786 GSK: formulation B

GSK1605786 formulation B will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.

DRUG

GSK1605786 GSK direct-fill: formulation C

GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.

DRUG

GSK1605786 GSK modified-process: formulation D

GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.

DRUG

GSK1605786 GSK tablet: formulation E

GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.

Trial Locations (1)

14202

GSK Investigational Site, Buffalo